Date: 2015-11-03
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Eli Lilly (USA - IN)
Product: LY3127804
Action
mechanism: monoclonal antibody. LY3127804 is a humanized and engineered lgG4 isotype antibody designed to bind to angiopoietin2 (Ang2) with high affinity and neutralize Ang2 induced phospho-Tie2. Angiopoietin2 (Ang2) promotes tumor angiogenesis and growth by destabilizing the Tie2-expressing vasculature, enhancing the endothelial cells' response to angiogenic stimuli such as vascular endothelial growth factor (VEGF), and inducing Tie2-independent integrin-mediated sprouting tip cell migration.
Disease: advanced solid tumors
Therapeutic area: Cancer - Oncology
Country: Belgium, France, Spain, USA
Trial
details: The main purpose of this study is to evaluate the safety of LY3127804 given as monotherapy and in combination with Ramucirumab for participants with advanced or metastatic solid tumors. The study will also include dose-expansion cohorts for participants with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma (GEJ) and hepatocellular carcinoma (HCC). ( NCT02597036)
Latest
news: * On November 3, 2015, a Phase I trial sponsored by Eli Lilly was published on the NIH website ClinicalTrials.gov for LY3127804 and is currently recruiting participants.
